Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
As is so often the case in medicine, data suggesting a positive finding from one study comes out at about the same time as data demonstrating exactly the opposite … and in prostate cancer this occurs all too frequently! … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: 5-ARI, benefit, dutasteride, finasteride, outcome, Prevention, risk | 29 Comments »
A poster at the Genitourinary Cancers Symposium yesterday will bring joy to Chuck Maack’s heart. It addressed the use of dutasteride in the off-therapy cycles of intermittent androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, dutasteride, intermittent | 4 Comments »
New data from the ARTS study, reported in European Urology, suggests that dutateride may have a role in the treatment of men with biochemical failure after radical first-line therapy for prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ARTS, biochemical progression, dutasteride, outcome, second-line | 2 Comments »
According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical specimens in a small percentage of men diagnosed with high-risk disease. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: abiraterone, dutasteride, enzalutamide, leuprolide, MDV3100, neoadjuvant, pre-surgical | 6 Comments »
According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: dutasteride, low risk, Prevention, progression | 5 Comments »
The American Urological Association (AUA) has written to the U.S. Food & Drug Administration (FDA) seeking modification of the FDA’s recent guidance on the use of 5α-reductase inhibitors like dutasteride and finasteride in the management of urologic conditions. … READ MORE …
Filed under: Management, Prevention, Treatment | Tagged: 5-ARI, dutasteride, FDA, finasterine, guidance, safety | 1 Comment »
Yesterday the US Food & Drug Administration (FDA) updated its guidance on the use of 5α-reductase inhibitors with specific reference to the risk that use of these products may be able to induce high-grade (and therefore high-risk) prostate cancer in a small subset of men treated with these agents. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, FDA, finasteride, Prevention, risk | 4 Comments »
It is becoming increasingly clear that the prevention, treatment, and management of prostate cancer is at an intellectual as well as a practical, clinical crossroads. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: dutasteride, finasteride, Prevention, PSA, screening, supplement, testing, testosterone | 2 Comments »
Monique Roobol and her colleagues continue to mine data from the ERSPC and other major trials in a serious attempt to describe processes that would allow us to identify the vast majority of clinically significant prostate cancers while avoiding the unnecessary diagnosis and over-treatment of indolent disease. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, chemoprevention, combination, Diagnosis, dutasteride, risk, screening | 1 Comment »
Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
… READ MORE
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: adjuvant, ADT, bicalutamide, CyberKnife, dutasteride, intermittent, pomegranate, SBRT, screening | 1 Comment »
A recent article in the Journal of General Internal Medicine argues that using 5α-reductase (5-ARI) therapy (i.e., with dutasteride or finasteride) to prevent the early onset of prostate cancer is not justified by the available data. … And we entirely agree, … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, finasteride, outcome, pomegranate, Prevention | 2 Comments »
The abstract for the presentation of the resulsts of the REDEEM trial (to be presented on Thursday at the Gentourinary Cancer Symposium in Orlando) was published this evening on the ASCO web site. The data show that dutasteride delayed progression of prostate cancer in a well-defined group of patients compared to placebo therapy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: dutasteride, localized, low risk, REDEEM | 9 Comments »
We will presumably be at least a little wiser about this issue when data from the REDEEM trial are presented at the Genitourinary Cancers Symposium in Orlando on Thursday; however, data from Canada already suggest that 5α-reductase inhibitors (5-ARIs) affect progression of low-risk forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: 5-ARI, active surveillance, dutasteride, finasteride, outcome, progression | 5 Comments »
Based on the 14 to 2 “against” vote of an Oncology Drugs Advisory Committee meeting late last year, the U.S. Food & Drug Administration has rejected the application to approve dutasteride (Avodart) for prevention of prostate cancer in men at potentially elevated risk for a future postive biopsy. … READ MORE …
Filed under: Drugs in development, Prevention | Tagged: dutasteride, FDA, Prevention | 5 Comments »
According to further analysis of data from the REDUCE trial, “… men who are taking dutasteride can be confident that the drug does not weaken the ability of PSA to find cancer if it develops. Rather, the drug enhances the ability to find cancer if PSA levels are rising.” … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, dutasteride, PSA, ris, risk | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site